JP2005510516A - Pharmaceutical composition comprising a Factor VII polypeptide and a protein S inhibitor - Google Patents

Abstract

The present invention relates to a composition comprising Factor VII or a Factor VII-related polypeptide and a protein S inhibitor, and uses thereof for treating bleeding episodes (eg, reducing clotting time, enhancing hemostasis or blood Increasing heel strength).

Description

Field of Invention

  The present invention relates to a pharmaceutical composition comprising Factor VII or a Factor VII-related polypeptide and a protein S inhibitor. The invention also provides a combination of Factor VII or a Factor VII related polypeptide and a protein S inhibitor for the manufacture of a medicament for treating or preventing a subject suffering from bleeding episodes. Regarding use. The present invention also relates to a method for treating bleeding episodes in a subject and a method for enhancing clot formation in a subject. The present invention also relates to kits containing these compounds.

Background of the Invention

  Haemostasis is a complex of tissue factor (TF) exposed to circulating blood after injury to the vessel wall and FVIIa present in the circulation in an amount corresponding to about 1% of the total FVII protein mass. Started by formation. This complex is anchored to cells with TF and activates FX to FXa and FIX to FIXa on the cell surface. FXa activates prothrombin to thrombin, which activates FVIII, FV, FXI, and FXIII. Furthermore, the limited amount of thrombin formed at this early stage in hemostasis also activates platelets. Following the action of thrombin on platelets, they change shape and expose charged phospholipids on their surface. This activated platelet surface forms a template for further FX activation and complete thrombin generation. At the activated platelet surface, further FX activation occurs via the FIXa-FVIIla complex formed on the surface of the activated platelet, and FXa still converts prothrombin to thrombin on the surface. . Thrombin then converts fibrinogen into fibrin that is insoluble and stabilizes the initial platelet plug. This process compartmentalizes, or localizes, the site where TF is expressed or exposed, thereby minimizing the risk of systemic activation of the coagulation system. The insoluble fibrin that forms the plug is further stabilized by cross-linking of fibrin fibers catalyzed by FXIII.

FVIIa is mainly present in plasma as a single-chain enzyme precursor, which is cleaved by FXa into its double-stranded active form FVIIa. Recombinant active factor VIIa (rFVIIa) has been developed as a pro-haemostatic drug. Administration of rFVIIa provides a rapid and highly effective pro-haemostatic response in hemophilia subjects with bleeding (the subjects cannot be treated with clotting factor products by antibody formation) . Also, bleeding subjects who are deficient in factor VII, or subjects who have a normal coagulation system but are experiencing excessive bleeding can be successfully treated with FVIIa. In these studies, undesirable rFVIIa side effects (particularly the occurrence of thromboembolism) were not encountered.

Extra (extra) exogenously administered FVIIa increases the formation of thrombin on the activated platelet surface. This occurs in hemophilia subjects who lack FIX or FVIII and therefore lack the most potent pathway for complete thrombin formation. In addition, excess FVIIa increases thrombin formation in the presence of platelets with reduced platelet count or defective function.

A commercial preparation of recombinant human FVIIa is sold as NovoSeven (R) (Novo Nordisk A / S, Denmark). NovoSeven (R) has been designated for the treatment of bleeding episodes in hemophilia A and B patients. NovoSeven (R) is the only recombinant FVIIa available on the market for effective and reliable treatment of bleeding episodes.

Protein C is a vitamin K-dependent serine protease of approximately 62.000 kDa and is involved in down-regulation of the hemostatic response. Activated protein C is identical to auto-prothrombin II-A. Protein C is synthesized in the liver as a single-chain precursor (enzyme precursor) having a length of 461 amino acids. Mature protein C consists of two polypeptide chains, 155 and 262 amino acids long, respectively. Protein C is activated on the surface of endothelial cells by thrombin conjugated to thrombomodulin (TM). Along with its cofactor (vitamin K-dependent protein S), activated protein C (APC) catalyzes the proteolytic degradation of membrane-bound thrombin activated forms (Va and VIIIa) of coagulation factors V and VIII. . This mechanism is important for local inhibition of blood clotting.

Thrombomodulin (TM) is a high affinity receptor for thrombin located in the endothelium. The dramatic changes in thrombin specificity are related to its binding to TM. TM-binding loses its procoagulant properties (ie the ability to activate fibrinogen and activate platelets and factors V, VIII and XIII), but is a potent activator of protein C. TM is present in the vascular surface of endothelial cells of arteries, veins, capillaries and lymphatic vessels. It is also present in low concentrations in platelets, in the epithelial squamous epithelium, in various cultured cells, and also in endothelial cell neoplasms. Soluble forms (probably proteolytic products) have been identified in human plasma and in urine. TM is an integral membrane protein and is synthesized as a single polypeptide chain. The mature glycoprotein contains 557 amino acids and produces apoprotein (molecular weight of 60.300 kDa). While activation of protein C by thrombin is slow, formation of thrombin-TM complexes (eg, on the surface of endothelial cells) results in a 20,000-fold increase in activation rate. Thrombin and TM form a 1.1 complex with high affinity.

Protein S is a vitamin K-dependent plasma protein that is synthesized in the liver, in endothelial cells, and in testicular Leydig cells. Protein S functions as a cofactor for APC in the degradation of Va and VIIIa, but its mechanism of action is unknown. Among the vitamin K-dependent proteins, protein S has the greatest affinity for negatively charged phospholipids and can increase the affinity of APC for this type of phospholipid. Indicated. Protein S and APC appear to form a 1: 1 complex at the lipid surface. Protein S and APC also interact with platelets, the surface of platelet microparticles, and endothelial cells. In the presence of APC, protein S binding increases more than 10-fold. The fact that protein S is also involved in the regulation of the classical pathway of the complement system is due to the fact that about 60% of protein S in human plasma occurs in high molecular weight, non-covalent complexes with C4b binding proteins. Has been advocated based on. Only free protein S functions as an APC cofactor.

The protein C anticoagulant system is of paramount importance for the control of blood clotting in vivo. This may be due to a severe thromboembolic disease affecting individuals with homozygous deficiency of protein C or protein S, and thrombosis in people who are deficient in any protein heterozygosity. Demonstrated by the high incidence of.

It is well known that subjects who bleed excessively following surgery or serious trauma and need blood transfusions will develop more complications than those who have not had any bleeding. However, also in moderate bleeding that requires administration of human blood or blood products (platelets, leukocytes, plasma derived concentrates for the treatment of coagulation defects, etc.), human viruses (hepatitis, HIV , Parvoviruses, and other currently unknown viruses) may cause complications related to the risk of transmitting. Massive bleeding that requires massive transfusions may lead to the development of multiple organ failure, including impaired lung and kidney function. Once a subject develops these serious complications, a cascade of events involving many cytokines and inflammatory responses is initiated, making any treatment extremely difficult and unfortunately often unsuccessful. Thus, the main goal in surgery as well as in the treatment of major tissue damage is to avoid or minimize bleeding. In order to avoid or minimize such bleeding, it is important to ensure the formation of stable and rigid haemostatic plugs that are not easily lysed by fibrinolytic enzymes. Furthermore, it is important to ensure the rapid and efficient formation of such plugs or clots.

Today, subjects suffering from bleeding episodes, including trauma victims and subjects bleeding with surgery, are often treated with some FVIIa injections or infusions, and the short half-life of FVIIa ( 2.5 hours), more than one dose is required to maintain a certain level of hemostatic ability. More rapid bleeding prevention would be an important benefit for such subjects. If so, the number of doses needed to stop bleeding and continue to stop bleeding will be reduced.

EP 225,160 (Novo Nordisk) relates to FVIIa compositions and methods for the treatment of bleeding disorders not caused by coagulation factor defects or coagulation factor inhibitors.

European Patent No. 82,182 (Baxter Travenol Lab.) Is a composition of Factor VIIa for use in a subject to combat blood coagulation factor defects or the effects of inhibitors on blood coagulation factors. About.

International Patent Publication No. WO 93/06855 (Novo Nordisk) relates to topical application of FVIIa.

In the art, the occurrence of bleeding; surgery, trauma, or other forms of tissue damage; induction of coagulopathy, including coagulopathy in multiple transfused subjects; decreased liver function (“liver disease”) Congenital or acquired clotting or bleeding disorders, including: impaired platelet function or decreased platelet count; deficiency or abnormality of “compounds” (eg, platelets or von Willebrand factor protein) essential for clotting There is still a need to improve treatment of subjects undergoing bleeding, including subjects with increased fibrinolysis; anticoagulation or thrombolytic therapy; or stem cell transplantation.

Improved, reliable and widely applicable in the art, enhances coagulation, ensures or enhances the formation of a stable hemostasis, or is convenient for a subject being treated There is still a need for a method that achieves complete hemostasis in subjects, particularly subjects with impaired thrombin production. There is also a need for a method that has reduced time for bleeding arrest.

Summary of the Invention

  One object of the present invention is to provide a composition that can be used effectively in the treatment or prevention of bleeding episodes and coagulation disorders.

A second object of the present invention is to provide a composition in a single unit dosage form that can be used effectively in the treatment or prevention of bleeding episodes or as a clot. Another object of the present invention is to provide a composition, method of treatment or kit that exhibits a synergistic effect.

It is a further object of the present invention to provide a composition, method of treatment, or kit that does not exhibit substantial side effects, such as systemic high level activation of the coagulation system.

Other objects of the present invention will become apparent by reading this specification.

In a first aspect, the present invention provides a pharmaceutical composition comprising Factor VII or a Factor VII-related polypeptide and a protein S inhibitor.

In a second aspect, the invention is a kit of parts comprising a therapeutic agent for the development of bleeding,

a) an effective amount of a preparation of Factor VII or a Factor VII-related polypeptide in a first unit dosage form, and a pharmaceutically acceptable carrier;
b) an effective amount of a preparation of protein S inhibitor in a second unit dosage form, and a pharmaceutically acceptable carrier; and c) a container means for containing said first and second unit dosage forms A kit comprising:

In a third aspect, the present invention provides the use of factor VII or a factor VII-related polypeptide in combination with a protein S inhibitor for the manufacture of a medicament for treating the development of bleeding in a subject. In a further aspect, the present invention provides the use of a composition according to any one of claims 1 to 18 for the manufacture of a medicament for treating the development of bleeding in a subject.

In its different embodiments, the drug reduces the time needed to obtain complete hemostasis, reduces the time required to maintain hemostasis, reduces the clotting time, and clot lysis time (clot It is for prolonging lysis time and for increasing clot strength.

In different embodiments, the drug is congenital, including surgery, trauma, or other forms of tissue damage; coagulopathy including coagulopathy in multiple transfused subjects; decreased liver function (“liver disease”) Or acquired coagulation or bleeding disorder; defective platelet function or decreased platelet count; deficiency or abnormality of essential coagulation “compounds” (eg, platelets or von Willebrand factor protein); increased fibrinolysis; anticoagulant therapy Or to treat a subject suffering from bleeding by thrombolytic therapy; or stem cell transplantation. In a series of embodiments, the bleeding occurs in organs such as the brain, inner ear region, eyes, liver, lungs, tumor tissue, gastrointestinal tract; in another series, it is in hemorrhagic gastritis and copious uterine bleeding Diffuse bleeding. In another set of embodiments, the onset of bleeding is acute haemarthroses (joint bleeding), chronic haemophilia arthropathy, hematoma (eg muscle, retroperitoneal, sublingual, and pharynx Posterior (retrophalygenal), bleeding in other tissues, hematuria (bleeding from the renal tract), cerebral bleeding, surgery (eg, hepatectomy), tooth extraction, and gastrointestinal bleeding (eg, UGI bleeding) ) Bleeding associated with surgery or trauma in a subject with In one embodiment, the drug is for treating the onset of bleeding in a subject due to trauma, or surgery, or reduced platelet count or activity.

In a further aspect, the present invention is a method for treating the development of bleeding in a subject, said method comprising, for a subject in need thereof, a label of factor VII or a factor VII-related polypeptide. Administering a first amount of a product and a second amount of a protein S inhibitor preparation, wherein the first and second amounts are both effective for treating bleeding. provide.

In a further aspect, the present invention is a method for reducing clotting time in a subject, said method comprising, for a subject in need thereof, a preparation of factor VII or a factor VII-related polypeptide And a second amount of a protein S inhibitor preparation, wherein the first and second amounts are both effective to reduce clotting time. provide.

In a further aspect, the present invention is a method for enhancing hemostasis in a subject, said method comprising, for a subject in need thereof, a first of a preparation of factor VII or a factor VII-related polypeptide preparation. Administering a second amount of a protein S inhibitor preparation, wherein the first and second amounts together provide a method that is effective to enhance hemostasis.

In a further aspect, the present invention is a method for extending clot lysis time in a subject, said method comprising, for a subject in need thereof, a factor VII or a factor VII-related polypeptide. Administering a first amount of a preparation and a second amount of a preparation of protein S inhibitor, said first and second amounts being both effective to prolong clot lysis time Provide a way to be.

In a further aspect, the present invention is a method for increasing clot strength in a subject, said method comprising, for a subject in need thereof, a marker of factor VII or a factor VII-related polypeptide. Administering a first amount of a product and a second amount of a protein S inhibitor preparation, wherein the first and second amounts are both effective to increase clot strength. Provide a method.

In one series of embodiments of the method, the factor VII or factor VII-related polypeptide and the protein S inhibitor are administered in a single unit dosage form.

In another series of embodiments, the factor VII or factor VII-related polypeptide and the protein S inhibitor comprise a first unit dosage form and a protein S inhibitor standard comprising a preparation of factor VII or a factor VII-related polypeptide. Administered in a second unit dosage form containing the product. In that series of embodiments, the first unit dosage form and the second unit dosage form are not administered more than 15 minutes apart.

In a further aspect, the present invention is a kit comprising a therapeutic agent for the development of bleeding,

d) an effective amount of Factor VII or a Factor VII-related polypeptide, and an effective amount of a protein S inhibitor, and a single unit dosage form of a pharmaceutically acceptable carrier; and
e) providing a kit comprising container means for containing the single unit dosage form.

In one series of embodiments of the invention, the factor VII or factor VII-related polypeptide is a factor VII-related polypeptide. In one series of embodiments of the invention, the factor VII-related polypeptide is a factor VII amino acid sequence variant. In one embodiment, the ratio between the activity of a factor VII-related polypeptide and the activity of native human factor VIIa (wild type FVIIa) is tested in an “in vitro hydrolysis assay” as described herein. At least about 1.25.

In one series of embodiments of the invention, the factor VII or factor VII-related polypeptide is factor VII. In one embodiment, the factor VII is human factor VII. In one embodiment, the Factor VII is bovine, porcine, dog, horse, mouse or salmon Factor VII. In another embodiment, the factor VII is made recombinantly. In another embodiment, the factor VII is derived from plasma. In a preferred embodiment, the factor VII is recombinant human factor VII. In one series of embodiments of the invention, the factor VII or factor VII-related polypeptide is its active form. In one preferred embodiment of the invention, the factor VII is recombinant human factor VIIa.

In one embodiment, the protein S inhibitor is Guglielmone & Vides, Thromb Haemost. 67: 46, 1992, selected from protein S inhibitors that can be identified in the assay described. In further embodiments, the protein S inhibitor is selected from polyclonal or monoclonal antibodies, or fragments thereof; polypeptides; oligopeptides; short peptides; or small organic molecules.

In one preferred embodiment, the factor VII polypeptide and protein S inhibitor are recombinant human factor VIIa and monoclonal anti-protein S antibodies.

In one embodiment, the factor VII or factor VII-related polypeptide and the protein S inhibitor are present in a mass ratio between about 100: 1 and about 1: 100 (w / w factor VII: protein S inhibitor). .

In one embodiment, the Factor VII-related polypeptide is an amino acid sequence variant that has been substituted, deleted, or inserted 20 amino acids or less compared to wild-type Factor VII (ie, US Patent No. 4 , 784, 950). In another embodiment, the Factor VII variant is substituted, deleted, or inserted by 15 amino acids or less; in other embodiments, the Factor VII variant is 8, 6 compared to the wild-type Factor VII. Less than 10 amino acids are substituted, deleted or inserted, such as 5, or 3 amino acids. In one embodiment, the Factor VII variant is selected from the following list: L305V-FVlla, L305V / M306D / D309S-FVlla, L305I-FVlla, L305T-FVlla, F374P-FVlla, V158T / M298Q-FVlla, V158D. / E296V / M298Q-FVlla, K337A-FVlla, M298Q-FVlla, V158D / M298Q-FVlla, L305V / K337A-FVlla, V158D / E296V / M298Q / L305V-FVla, V158D / E296 / M298Q / L305V / K337A-FVlla, K157A-FVII, E296V-FVII, E296V / M2 8Q-FVII, V158D / E296V-FVII, V158D / M298K-FVII, and S336G-FVII.

In a further aspect, the Factor VII related polypeptide has increased tissue factor independent activity compared to native human coagulation factor VIIa. In another embodiment, the increased activity is not accompanied by a change in substrate specificity. In another embodiment of the invention, the binding of factor VII-related polypeptide to tissue factor is not impaired, and the factor VII-related polypeptide has at least the activity of wild-type factor VIIa when bound to tissue factor.

In one embodiment, clotting time is reduced in mammalian blood. In another embodiment, hemostasis is enhanced in mammalian blood. In another embodiment, clot lysis time is prolonged in mammalian blood. In another embodiment, clot strength is increased in mammalian blood. In one embodiment, the mammalian blood is human blood. In another embodiment, the mammalian blood is normal human blood; in one embodiment, the blood is from a subject with impaired thrombin production. In one embodiment, the blood is blood from a subject having a deficiency in one or more clotting factors; in another embodiment, the blood has a subject having an inhibitor to one or more clotting factors. In one embodiment, the blood is from a subject with reduced fibrinogen concentration; in one embodiment, the blood is human blood deficient in a protein S inhibitor. It is. In one series of embodiments, the blood is plasma.

In one embodiment of the invention, factor VII or a factor VII-related polypeptide, and protein S inhibitor are the only hemostatic agents included in the composition. In another embodiment, factor VII or factor VII-related polypeptide and protein S inhibitor are the only active hemostatic agents included in the composition. In another embodiment, factor VII or a factor VII-related polypeptide and protein S inhibitor are the only clotting factors administered to the subject. In one embodiment of the invention, factor VII or factor VII-related polypeptide and protein S inhibitor are the only active agents administered to the patient. In one embodiment, the composition is substantially free of thrombin or prothrombin; in another embodiment, the composition is substantially free of FX; in another embodiment, the composition is substantially free of Does not contain FXa.

In another embodiment, the pharmaceutical composition is formulated for intravenous administration, preferably injection or infusion, especially injection. In one embodiment, the composition comprises at least one pharmaceutically acceptable excipient or carrier.

In one embodiment of the invention, the composition is a single unit dosage form, which includes both clotting factors. In one embodiment of the invention, the composition comprises a preparation of factor VII or a factor VII-related polypeptide as a first unit dosage form and a preparation of a protein S inhibitor as a second unit dosage form, And in the form of a kit of parts including container means for containing the first and second unit dosage forms. In one embodiment, the composition or kit further includes instructions for administering each of the compositions or separated components as applicable.

In one embodiment of the invention, the factor VII or factor VII-related polypeptide and the protein S inhibitor are administered in a single-dosage form. In one embodiment of the invention, the factor VII or factor VII-related polypeptide and the protein S inhibitor comprise a first unit dosage form comprising a factor VII or factor VII-related polypeptide preparation and a protein S inhibitor mark. Administered in a second unit dosage form containing the product.

In one embodiment of the invention, the factor VII or factor VII-related polypeptide and the protein S inhibitor are administered simultaneously. In another embodiment, the factor VII or factor VII-related polypeptide and the protein S inhibitor are administered sequentially. In one embodiment, the factor VII or factor VII-related polypeptide and the protein S inhibitor are not administered separated by more than 15 minutes, preferably 10 minutes, more preferably 5 minutes, more preferably more than 2 minutes. In one embodiment, the factor VII or factor VII-related polypeptide and the protein S inhibitor are up to 2 hours, preferably 1-2 hours, more preferably up to 1 hour, more preferably 30 minutes to 1 hour, more preferably Are administered up to 30 minutes apart, more preferably 15-30 minutes apart.

In one embodiment, the effective amount of Factor VII or Factor VII-related polypeptide is from about 0.05 mg / day to about 500 mg / day (70 kg subject). In one embodiment, an effective amount of a protein S inhibitor preparation is about 0.01 mg / day to about 500 mg / day (70 kg subject).

In one embodiment, the factor VII or factor VII-related polypeptide and the protein S inhibitor are present in a mass ratio between about 100: 1 and about 1: 100 (w / w factor VII: protein S inhibitor). .

In one embodiment of the invention, the pharmaceutical composition is a single unit dosage form and consists essentially of a preparation of factor VII or a factor VII-related polypeptide, as well as a preparation of a protein S inhibitor, and a pharmaceutical. Consisting of one or more ingredients selected from the list of pharmaceutically acceptable carriers, stabilizers, surfactants, neutral salts, antioxidants, preservatives, and protease inhibitors.

In another aspect of the invention, the pharmaceutical composition comprises essentially a preparation of Factor VII or a Factor VII-related polypeptide as well as a pharmaceutically acceptable carrier, stabilizer, surfactant, neutral salt, A first unit dosage form comprising one or more ingredients selected from a list of oxidizing agents, preservatives, and protease inhibitors, a preparation of essentially protein S inhibitor and a pharmaceutically acceptable carrier And a second unit dosage form comprising one or more ingredients selected from the list of stabilizers, surfactants, neutral salts, antioxidants, preservatives, and protease inhibitors It is a form.

In a further embodiment, the subject is a human; in another embodiment, the subject has impaired thrombin generation; in one embodiment, the subject has a decreased plasma concentration of fibrinogen. (Eg, a subject who has been transfused multiple times); In one embodiment, the subject has a reduced plasma concentration of Factor VIII or FIX.

In another aspect, the present invention relates to a method for enhancing hemostasis in a subject suffering from factor VII responsive syndrome as compared to when the subject is treated with factor VII as the only coagulation protein, The method comprises administering to a subject in need thereof a first amount of a preparation of factor VII or a factor VII-related polypeptide and a second amount of a preparation of a protein S inhibitor. Wherein the first and second amounts are both effective methods for enhancing hemostasis.

In another aspect, the present invention relates to a method for enhancing thrombin formation in a subject, said method comprising, for a subject in need thereof, a preparation of factor VII or a factor VII-related polypeptide. And a second amount of a protein S inhibitor preparation, wherein the first and second amounts are both effective methods for enhancing thrombin formation. .

In another aspect, the present invention relates to a method of enhancing thrombin formation in a subject suffering from factor VII responsive syndrome as compared to treating the subject with factor VII as the only coagulation protein. The method administers to a subject in need thereof a first amount of a preparation of factor VII or a factor VII-related polypeptide and a second amount of a preparation of protein S inhibitor Wherein the first and second amounts are both effective methods for enhancing thrombin formation.

In another aspect, the invention provides hemostasis in a subject suffering from a factor VII responsive syndrome as compared to the number of doses required when the subject is administered factor VII as the only coagulation factor protein. A method for reducing the number of clotting factor protein doses required to achieve the above, said method comprising, for a subject in need thereof, a first of a preparation of factor VII or a factor VII-related polypeptide preparation. And a second amount of a protein S inhibitor preparation, wherein the first and second amounts are both in a manner effective to reduce the number of clotting factor protein doses. is there.

In another aspect, the present invention relates to a method of treating bleeding in a subject suffering from factor VII responsive syndrome, wherein the method is directed against a subject in need thereof for factor VII or factor VII. Administering a first amount of a preparation of related polypeptides and a second amount of a preparation of protein S inhibitor, wherein the first and second amounts are both effective in treating bleeding. Is the method.

In one embodiment, the factor VII is human recombinant factor VIIa (rFVIIa). In another embodiment, the rFVIIa is Novo Seven® (Novo Nordisk A / S, Bagsvaard, Denmark).

In another aspect, the present invention relates to the use of factor VII or a factor VII-related polypeptide in combination with a protein S inhibitor for the manufacture of a medicament for enhancing fibrin clot formation in mammalian plasma.

In another aspect, the invention relates to a method for enhancing fibrin clot formation in a subject, said method comprising, for a subject in need thereof, a preparation of factor VII or a factor VII-related polypeptide. And a second amount of a protein S inhibitor preparation, wherein the first and second amounts are both effective methods for treating bleeding.

Detailed Description of the Invention

  Subjects who bleed excessively in connection with surgery or serious trauma and need a blood transfusion will develop more complications than those who have not experienced any bleeding. However, if they require the administration of human blood or blood products (platelets, leukocytes, plasma-derived concentrates, etc. for the treatment of coagulation defects), this may cause human viruses (eg, hepatitis, HIV , Parvovirus, or other currently unknown virus) as well as non-viral pathogens, moderate bleeding may cause complications. Massive bleeding that requires massive transfusions may lead to the development of multiple organ failure, including impaired lung and kidney function. Once a subject develops these serious complications, a cascade of events involving many cytokines and inflammatory responses is initiated, making any treatment extremely difficult and unfortunately often unsuccessful. Patients who experience most blood loss become clinically unstable. Such patients are at risk of undergoing atrial fibrillation, thereby causing a fatal cessation of cardiac activity; renal dysfunction; or fluid extravasation in the lungs (so-called “wet lungs”). Or ARDS). Thus, the main goal in surgery as well as in the treatment of major tissue damage is to avoid or minimize bleeding. In order to avoid or minimize such unwanted bleeding, it is important to ensure the formation of a stable and solid hemostasis that is not easily dissolved by fibrinolytic enzymes. Furthermore, it is important to ensure the rapid and efficient formation of such plugs or clots.

In addition, subjects with thrombocytopenia (decreased platelet count or activity) may be prone to lysis in the middle due to impaired thrombin generation and incomplete stabilization of the fibrin plug. Causes blood clots. In addition, subjects with significant trauma or organ damage often result in frequent blood transfusions, decreased platelet counts, and decreased levels of fibrinogen, factor VIII, and other clotting proteins. . These subjects experience an impairment (or reduction) in thrombin generation.
Thus, in these subjects, hemostasis is defective or has little effect and will form a fibrin plug that is easily and partially dissolved by proteolytic enzymes, and such enzymes Released extensively in aspects characterized by extensive trauma and organ damage.

Tissue bleeding can also form haematomas. The size of the hematoma (especially in the skull and spinal cord) can indicate the degree of nerve function loss, difficulty in rehabilitation, and / or the severity of permanent impairment of nerve function after rehabilitation and It is closely related to the degree. The most severe hematoma results are seen when they are located in the brain, which will cause even the death of the patient.

Thus, the primary goal in the treatment of bleeding is to provide hemostasis in the shortest amount of time and thus keep blood loss to a minimum.

Thus, the present invention provides beneficial compositions, uses, and methods of treatment for the treatment of bleeding episodes in subjects in need of such treatment. The compositions, uses, and methods reduce blood loss before hemostasis is performed, reduce blood required during surgery, and maintain blood pressure at an acceptable level until hemostasis occurs. More rapid stabilization of blood pressure, shortening the recovery time of treated patients, reducing rehabilitation time of treated patients, reducing the formation of hematomas including brain hematomas or reducing the formation of hematomas That can be associated with beneficial effects such as rapid bleeding suppression, cessation of bleeding and a reduction in the number of doses required to maintain hemostasis.

When either factor VIIa or protein S inhibitor is administered alone by administering a factor VII or factor VII-related polypeptide, eg, a factor VIIa sample, in combination with a protein S inhibitor preparation Compared to clotting time, clot firmness, and resistance, there is a reduction in clotting time, firm clots, and increased resistance to fibrinolysis.

Also, either factor VIIa or protein S inhibitor is administered alone by administering factor VII or a factor VII-related polypeptide, such as a factor VIIa sample, in combination with a protein S inhibitor sample. Compared to occasional circumstances, there is a reduction in time to prevent bleeding and a reduction in the number of doses to maintain hemostasis. The present invention provides beneficial effects in simultaneous or sequential dosing of a protein S inhibitor preparation and a preparation of factor VII or a factor VII-related polypeptide. The pharmaceutical composition according to the present invention may be in the form of a single composition or may be in the form of a multi-component kit (part kit). The compositions according to the present invention are useful as therapeutic and prophylactic clots in mammals including primates such as humans. The present invention further provides a method for treating (including prophylactically treating or preventing) the development of bleeding in a subject, including a human.

The first or second or third other unit doses are referred to throughout this specification, but this is merely for convenience purposes, rather than indicating the preferred order of administration.

The combination of a Factor VII or Factor VII-related polypeptide preparation and a protein S inhibitor preparation is an advantageous product that ensures a short clotting time, rapid formation of a thrombus, and a stable formation of a thrombus . The inventor of the present invention that the combination of factor VII or factor VII-related polypeptide and protein S inhibitor is an advantageous product that ensures the formation of a solid, stable and rapidly formed thrombus Was found by.

The inventors of the present invention have shown that the combination of factor VIIa and protein S inhibitor can increase clot firmness more efficiently than either factor VIIa or protein S inhibitor alone. Also, the combination of factor VII or a factor VII-related polypeptide and protein S inhibitor prolongs the in vitro clot lysis time in normal human plasma more efficiently than either factor VIIa or protein S inhibitor alone It was shown that Also, half-clot lysis time (half-clot in normal human plasma is more efficient than the combination of factor VII or factor VII-related polypeptide and protein S inhibitor than either factor VIIa or protein S inhibitor alone. It has been shown that the lysis time can be extended. In addition, the combination of factor VII or a factor VII-related polypeptide and a protein S inhibitor is more efficient than either factor VIIa or protein S inhibitor alone in fibrinolysis in normal human plasma, particularly protein S inhibitors. It has been shown that clots can be protected from mediated fibrinolysis. Therefore, by enhancing coagulation, a more effective treatment of the subject's bleeding can be obtained.

While not wishing to be obligated by theory, it is believed that complete thrombin generation is necessary to form a robust and stable hemostatic clot and, consequently, to maintain hemostasis. The fibrin structure of such a plug is dependent on both the amount of thrombin formed and the initial rate of thrombin generation. In the presence of obstructive thrombin generation, a highly permeable porous fibrin plug is formed. Fibrinolytic enzymes present on the fibrin surface usually readily dissolve such fibrin plugs. Also, the formation of a stable fibrin plug is dependent on the presence of factor XIIIa activated by thrombin and is therefore also dependent on complete thrombin generation. Furthermore, the recently described thrombin-activatable fibrinolysis inhibitor TAFI requires rather large amounts of thrombin for its activation. Thus, in the presence of thrombin formation that is not fully satisfactory, TAFI is not activated, and normal fibrinolytic activity results in simpler thrombosis formation than is normally degraded. In thrombocytopenia, a situation where the platelet count has decreased, administration of extra exogenous factor VIIa initiates more rapid thrombin generation. However, total thrombin production is not normalized even by high concentrations of factor VIIa.

Complete thrombin activation does not occur in subjects with reduced plasma concentrations of fibrinogen (subjects who have been transfused multiple times as a result of many traumas or extensive surgery). More effective hemostasis is then achieved by administration of a combination of Factor VII or a Factor VII-related polypeptide and a protein S inhibitor.

Subjects with thrombocytopenia result in impaired thrombin generation as well as fibrin plug stabilization defects, resulting in a thrombus that is prone to dissolution in the middle. In addition, subjects with significant trauma or organ damage often result in frequent blood transfusions, decreased platelet counts, and decreased levels of fibrinogen, factor VIII, and other clotting proteins. . These subjects experience an impairment (or reduction) in thrombin generation. In addition, these decreased fibrinogen levels negatively interfere with factor XIII activation. Therefore, these subjects are either deficient in hemostasis or are less efficient and are released extensively by proteolytic enzymes, in addition to situations where such enzymes are characterized by extensive trauma and organ damage This causes the formation of a fibrin plug that is easily and partially dissolved.

In order to facilitate the formation of a fully stabilized plug with full ability to maintain the subject's hemostasis, the compositions of the invention are administered. This composition is particularly beneficial in subjects with reduced platelet counts and in subjects with reduced plasma levels of fibrinogen and / or other clotting proteins.

Factor VII polypeptide:
In practicing the present invention, any factor VII polypeptide that is effective to prevent or treat bleeding may be used. This includes factor VII polypeptides derived from blood or plasma, or produced by recombinant means.

The present invention includes Factor VII polypeptides such as those having the amino acid sequence disclosed in, for example, US Pat. No. 4,784,950 (wild type human Factor VII). In some embodiments, the factor VII polypeptide is human factor VIIa, for example, as disclosed in US Pat. No. 4,784,950 (wild type factor VII). In a series of embodiments, the Factor VII polypeptide has at least about 10%, preferably at least about 30%, more preferably at least about 50%, and most preferably at least about 70% human factor VIIa biospecific activity. a polypeptide exhibiting activity). In a series of embodiments, the Factor VII polypeptide comprises at least about 90%, preferably at least about 100%, preferably at least about 120%, more preferably at least about 140%, and most preferably at least about 160% human Factor VIIa. Including a polypeptide exhibiting a specific biological activity. In a series of embodiments, the Factor VII polypeptide has at least about 70%, preferably at least about 80%, more preferably at least about 80% of the sequence of wild-type Factor VII as disclosed in US Pat. No. 4,784,950. Polypeptides exhibiting 90% and most preferably at least about 95% identity.

As used herein, a “Factor VII polypeptide” includes, but is not limited to, Factor VII as well as Factor VII-related polypeptides. The term “Factor VII” refers to wild type human Factor VII (disclosed in US Pat. No. 4,784,950) and other species such as, for example, cattle, pigs, dogs, mice, and salmon Factor VII. It is contemplated to include, but is not limited to, a polypeptide having the amino acid sequence 1-406 of the wild type factor VII from which the factor VII is derived from blood or plasma or produced by recombinant means . This further includes natural allelic variations of factor VII that will persist and emerge from one individual to another. Also, the degree and site of glycosylation or other post-translational modifications may vary depending on the host cell chosen and the nature of the host cell environment. The term “Factor VII” also refers to the uncut (enzyme precursor) form of a Factor VII polypeptide as well as Factor VIIa that has been proteolytically processed to produce each of these bioactive forms. It is contemplated to include Typically, factor VII is cleaved between residues 152 and 153 to produce factor VIIa.

A “Factor VII-related polypeptide” is chemically modified compared to human Factor VII and / or includes one or more amino acid sequence changes compared to human Factor VII (ie, a Factor VII variant) And / or any factor VII polypeptide including, but not limited to, a truncated amino acid sequence compared to human factor VII (ie, a factor VII fragment). Such factor VII-related polypeptides may exhibit different properties, including stability, phospholipid binding, altered specific activity, and the like compared to human factor VII.
The term “Factor VII-related polypeptide” refers to an uncut (enzyme precursor) form of a polypeptide as well as a “VIIa-related polypeptide” that has been proteolytically processed to produce their respective bioactive forms, or It is contemplated to include what are referred to as “activated factor VII-related polypeptides”.

As used herein, a “Factor VII-related polypeptide” is a polypeptide that exhibits substantially the same or improved biological activity as compared to wild-type human Factor VII, as well as wild-type human VIIa. Including, but not limited to, a polypeptide in which factor VIIa biological activity is substantially modified or reduced compared to the activity of the factor.
These polypeptides include chemically modified factor VII or factor VIIa and specific amino acid sequence changes introduced into the polypeptide to modify or disrupt the bioactivity of the factor VII. It is not limited to.

In addition, a polypeptide having a slightly modified amino acid sequence, such as a polypeptide having a modified N-terminus containing a deletion or addition of the N-terminal amino acid, and / or chemically modified compared to human Factor Vila Polypeptides.

Factor VII-related polypeptides, including variants of Factor VII, exhibit substantially the same or superior physiological activity as wild-type factor VII, or instead are substantially modified compared to wild-type factor VII; Or a polypeptide having an amino acid sequence that differs from that of wild-type factor VII by insertion, deletion, or substitution of one or more amino acids, whether or not it exhibits reduced bioactivity .

A Factor VII-related polypeptide comprising a variant is a wild-type Factor VIIa produced in the same cell type when tested in one or more of a clotting assay, proteolytic assay, or TF binding experiment as described above. At least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least Including those exhibiting about 80%, at least about 90%, at least about 100%, at least about 110%, at least about 120%, or at least about 130%.

Factor VII-related polypeptides, including variants, have substantially the same or improved biological activity compared to wild-type factor VIIa and can be used as described above for clotting assays, proteolytic assays, or TF binding experiments. At least about 25%, preferably at least about 50%, more preferably at least about 75%, more preferably at least about the specific activity of wild-type factor VIIa produced in the same cell type when tested in one or more of Including those exhibiting about 100%, more preferably at least about 110%, more preferably at least about 120%, and most preferably at least about 130%.

A Factor VII-related polypeptide comprising a variant and having substantially the same or improved biological activity compared to wild-type Factor VIIa can be used in clotting assays, proteolytic assays, or TF binding experiments as described above. When tested in one or more, at most about 25%, preferably at most about 10%, more preferably at most about 5% of the specific activity of wild-type factor VIIa produced in the same cell type, most preferably Represents at most about 1%. Factor VII variants with substantially modified biological activity compared to wild-type factor VII bind to TF variants that exhibit TF-independent factor X proteolytic activity, and TF, while factor X However, it is not limited to these.

In some embodiments, the Factor VII polypeptide is a Factor VII related polypeptide, particularly a variant, when tested here in an “in vitro hydrolysis assay” (see “Assays” below). In addition, the ratio between the activity of the Factor VII polypeptide and the activity of native human Factor VIIa (wild type FVIIa) is at least about 1.25.25; in other embodiments, the ratio is at least about 2. In a further embodiment, the ratio is at least about 4.0. In some embodiments of the invention, the Factor VII polypeptide is a Factor VII-related polypeptide, in particular a variant, here in an “in vitro proteolytic assay” (see “Assay” below). When tested, the ratio between the activity of the Factor VII polypeptide and the activity of native human Factor VIIa (wild type FVIIa) is at least about 1.25; in other embodiments, the ratio is at least about 2 In a further aspect, the ratio is at least about 4.0; in a further aspect, the ratio is at least about 8.0.

In some embodiments, the factor VII polypeptide is human factor VII, for example, as disclosed in US Pat. No. 4,784,950 (wild type factor VII). In some embodiments, the factor VII polypeptide is human factor VIIa. In a series of embodiments, the Factor VII polypeptide exhibits at least about 10%, preferably at least about 30%, more preferably at least about 50%, and most preferably at least about 70% of the biospecific activity of human Factor VIIa. A factor-related polypeptide. In some embodiments, the Factor VII polypeptide has an amino acid sequence that differs from that of wild-type Factor VII by one or more amino acid insertions, deletions, or substitutions.

Non-limiting examples of variants of factor VII that have substantially the same or superior biological activity compared to wild type factor VIIa correspond to Danish patent application numbers PA2000 00734 and PA2000 01360 (WO 01/83725) And those described in PA 2000 01361 (corresponding to WO 02/22776), but are not limited thereto. Non-limiting examples of Factor VII variants with biological activity substantially equivalent or improved to wild-type Factor VII include S52A-FVII, S60A-FVII (lino et al., Arch. Biochem. Biophys. 352: 182-192 , 1998); L305V-FVII, L305V / M306D / D309S-FVII, L305I-FVII, L305T-FVII, F374P-FVII, V158T / M298Q-FVII, V158D / E296V / M298Q-FVII, K337A-98 V158D / M298Q-FVII, L305V / K337A-FVII, V158D / E296V / M298Q / L305V-FVII, V158D / E296V / M298Q / K337A-FVI V158D / E296V / M298Q / L305V / K337A-FVII, K157A-FVII, E296V-FVII, E296V / M298Q-FVII, V158D / E296V-FVII, V158D / M298K-FVII, and S336G-F No. 5, S336G-F , 560, an FVIIa variant exhibiting increased proteolytic stability; Factor VIIa cleaved by proteolysis between residues 290 and 291 or between residues 315 and 316 ( Mollerup et al., Biotechnol. Bioeng. 48: 501-505, 1995); and the oxidized form of Factor Vila (Kornfeld et al., Arch. Biochem. Biophys. 363: 43-54, 199). ) Including the. Non-limiting examples of Factor VII variants with substantially reduced or modified biological activity compared to wild type Factor VII are R152E-FVIIa (Wildgoose et al., Biochem 29: 3413-3420, 1990), S344A. -FVIIa (Kazama et al., J. Biol. Chem. 270: 66-72, 1995), FFR-FVIIa (Holst et al., Eur. J. Vasc. Endovasc. Surg. 15: 515-520, 1998), and Gla domain. Factor VIIa that lacks (Nicolaisen et al., FEBS Letts. 317: 245-249, 1993).
Non-limiting examples of chemically modified factor VII polypeptides and sequence variants are described, for example, in US Pat. No. 5,997,864.

The biological activity of factor VIIa in blood coagulation includes (i) its ability to bind to tissue factor (TF), and (ii) factor IX activated by catalyzing proteolytic cleavage of factor IX or factor X or Derived from the ability to produce factor X (factor IXa or factor Xa, respectively).

For purposes of the present invention, the biological activity of a Factor VII polypeptide (“Factor VII biological activity”) is determined by, for example, plasma and thromboplastin deficient in Factor VII, as described in US Pat. No. 5,997,864. In this assay, which may be quantified by measuring the ability of the preparation to promote blood clotting, the biological activity is expressed as a decrease in clotting time compared to the subject sample, 1 unit / ml Is converted to "factor VII units" by comparison with a pooled human serum standard containing the factor VII activity of Alternatively, factor VIIa biological activity is:

(I) measuring the ability of factor VIIa or a factor VIIa-related polypeptide to produce activated factor X (factor Xa) in a system comprising TF embedded in a lipid membrane and factor X (Persson et al., J. Biol. Chem. 272: 19919-19924, 1997);
(Ii) measuring the hydrolysis of factor X in an aqueous system (see “In Vitro Proteolysis Assay”, see below);
(Iii) measuring the physical binding of Factor VIIa or Factor VIIa related polypeptide to TF using an instrument based on surface plasmon resonance (Persson, FEBS Letts. 413: 359-363, 1997); and,
(Iv) measuring hydrolysis of the synthetic substrate by Factor VIIa and / or Factor VIIa related polypeptides (see “In Vitro Hydrolysis Assay”, see below);
(V) Quantification may be performed by measuring thrombin generation in an in vitro system independent of TF.

The terms “factor VII biological activity” or “factor VII activity” are intended to include the ability to generate thrombin; the term is used in the surface of platelets activated in the absence of tissue factor. Including the ability to generate

A Factor VIIa preparation that may be used in accordance with the present invention is, but is not limited to, NovoSeven® (Novo Nordisk AIS, Bagsvaard, Denmark).

Protein S Inhibitors The present invention includes, but is not limited to, for example, chimeric, humanized, and fully human antibodies, or fragments thereof (eg, Fab, Fab ′, F (ab ′) 2 and F (v)) Polypeptides; oligopeptides; short peptides; or the use of inhibitors of protein S such as small organic molecules.

The term antibody is used herein to mean an immunoglobulin molecule and an immunologically active portion of an immunoglobulin molecule, ie, a molecule that contains an antibody binding site or paratope. Exemplary antibody molecules include intact immunoglobulin molecules, regions of immunoglobulin molecules containing substantially intact immunoglobulin molecules and paratopes (Fab, Fab ′, F (ab ′) in the art). 2 and the region known as F (v). Accordingly, within the definition of antibody are also included antibody fragments that retain the ability to specifically bind to an antigen (eg, human protein S). It has been shown that the antigen-binding function of an antibody can function with full-length antibody fragments. Examples of binding fragments included within the term “antibody” include (i) Fab fragments (monovalent fragments consisting of VL, VH, CL and CH1 domains); (ii) F (ab) 2 and F (ab ') Two fragments (a divalent fragment containing two Fab fragments linked by a disulfide bridge at the hinge region); (iii) an Fd fragment consisting of the VH and CH1 domains; (iv) the VL of one arm of the antibody and An Fv fragment consisting of the VH domain; (v) a dAb fragment consisting of the VH domain (Ward, ES et al., Nature 341: 544-546); and (vi) an isolated complementarity determining region (CDR) included. Furthermore, although the two domains (VL and VH) of the Fv fragment are encoded by separate genes, they can be ligated using recombinant techniques, and this ligation results in a single It is made by a synthetic linker that can be made as a protein chain (known as a single chain Fv (scFv), in which the VL and VH regions form a monovalent molecule in pairs). Such single chain antibodies are also intended to be encompassed within the term “antibody”. Other forms of single chain antibodies are also included, such as diabodies. Diabodies are bispecific antibodies that are bivalent and have VH and VL domains expressed on a single polypeptide chain, but paired between two domains on the same chain To allow the domain to pair with the complementary domain of another chain and create two antigen binding sites (see, for example, Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90: 6444-6448; Poljak, RJ, et al. (1994) Structure 2: 1121-1123).

A protein S inhibitor is a compound that reduces the biological activity of protein S to at least about 50%, preferably at least about 75%, more preferably at least about 90% when tested in a protein S assay as described. including. For the purposes of the present invention, the biological activity of protein S is described in Guglielmone & Vides, Thromb Haemost. 67: 46, 1992 can be quantified ("Protein S inhibition assay").

Non-limiting examples of protein S inhibitors are also known as natural inhibitors of protein S, protein S inhibitor (PCI), plasminogen activator inhibitor 3 (PAI-3) (see, eg, Elisan et al.,). Blood 91: 1542, 1998), and PCI variants and equivalent polypeptides; α-2-macroglobulin (eg, described by Cvirn et al., Haemostasis 31: 1, 2001); α- 1-antitrypsin (for example, described by Elisan et al., Blood 91: 1542, 1998) is included.

As used herein, “PCI polypeptide” includes, but is not limited to, PCI, as well as PCI-related polypeptides. A “PCI-related polypeptide” includes, but is not limited to, a PCI polypeptide, wherein the PCI polypeptide has been chemically modified compared to human PCI and / or compared to human PCI. Either containing one or more amino acid sequence changes (ie, PCI variants) and / or containing truncated amino acid sequences compared to human PCI (ie, PCI fragments). Such PCI-related polypeptides may exhibit different properties, including stability, binding properties, altered specific activity, and the like compared to human PCI.

Definitions In the present invention, the three-letter or single-letter designations of amino acids are used in their conventional meaning as shown in Table 1. Unless explicitly indicated, the amino acids referred to herein are L amino acids. For example, the first letter in K337 represents the naturally occurring amino acid at the indicated position of wild-type factor VII, and for example, [K337A] -FVIIa is a single letter that occurs naturally at the indicated position. It is understood that the amino acid represented by the code K represents an FVII-variant substituted with the amino acid represented by the single letter code A.

The terms “Factor VIIa” or “FVlla” may be used interchangeably.

In this context, a “subject with a disorder of thrombin generation” means a subject who is unable to generate a complete thrombin burst on the activated platelet surface, with normal amounts and functions of clotting factors, platelets And a subject having less thrombin production than thrombin production in a subject with a fully functioning, normal hemostatic system, including fibrinogen (eg, pooled, normal human plasma) and VIIl Subjects lacking factors; subjects with reduced platelet count or defective platelets (eg, subjects with thrombocytopenia or Granzmann thrombophilia or heavy bleeding); decreased levels of prothrombin, FX or FVII Subject; subjects with reduced levels of some coagulation factors If, due to excessive bleeding result of trauma or extensive surgery); and subjects the plasma concentration of fibrinogen was reduced (e.g., including multidose transfused subject), but is not limited.

“Level of thrombin generation” or “normal thrombin generation” means the level of a patient's level of thrombin generation compared to the level of a healthy subject. The level is expressed as a percentage of the normal level. The terms are used interchangeably where appropriate.

The term “enhanced hemostatic system” means an enhanced ability to produce thrombin. The term “enhance hemostasis” is used when the thrombin generation measured on a test sample comprising a preparation of factor VII or a factor VII-related polypeptide and a preparation of protein S inhibitor is tested in the same thrombin generation assay. , A term intended to include an extended situation compared to individual thrombin generation in a subject sample containing only factor VII or a factor VII-related polypeptide or protein S inhibitor, respectively. Thrombin generation may be assayed as described in the thrombin generation assay described herein (see “Assay Methods”).

As used herein, a “Sole” agent or factor is the only hemostatic agent or factor VII or factor VII-related polypeptide and protein S inhibitor, together in a pharmaceutical composition or kit. A situation where it is an active hemostatic agent or coagulation factor, or is the only hemostatic agent or active hemostasis agent or coagulation factor administered to a patient in the course of a particular treatment, such as in the course of development of a particular bleeding Say. It is understood that these situations include those where other hemostatic agents or clotting factors are not present in sufficient amounts or activity as applicable, so as to significantly affect one or more clotting parameters. The

Clot lysis time, clot strength, fibrin clot formation, and clotting time are clinical parameters used to assess the status of the patient's hemostatic system. Blood samples are drawn from the patient at appropriate intervals, eg, Meh et al., Blood Coagulation & Fibrinolysis 2001; 12: 627637; Vig et al., Hematology, Vol. 6 (3) pp. 205-213 (2001); Vig et al., Blood coagulation & fibrinolysis, Vol. 12 (7) pp. 555-561 (2001) Oct; Glidden et al., Clinical and applied thrombosis / hemostasis, Vol. 6 (4) pp. 226-233 (2000) Oct; McKenzie et al., Cardiology, Vol. 92 (4) pp. 240-247 (1999) Apr; or Davis et al., Journal of the American Society of Nephrology, Vol. 6 (4) pp. 1250-1255 (1995), one or more parameters are assayed by thromboelastography.

The term “prolonging the clot lysis time” means that the clot lysis time measured for a test sample comprising a preparation of factor VII or a factor VII-related polypeptide and a preparation of protein S inhibitor is the same clot. A term intended to include an extended situation when tested in a lysis assay as compared to individual clot lysis times in a subject sample each containing only factor VII or a factor VII-related polypeptide or protein S inhibitor, respectively. It is. The clot lysis time may be assayed as described above.

The term “increasing clot strength” refers to the clot strength (eg, mechanical strength) measured for a test sample comprising a preparation of factor VII or a factor VII-related polypeptide and a preparation of protein S inhibitor. Includes an increased situation compared to the individual clot lysis time in a subject sample each containing only factor VII or factor VII-related polypeptide or protein S inhibitor when tested in the same clot strength assay Is a term that contemplates Blood clot strength is described, for example, in Carr et al. (Carr ME, Zekert SL. Measurement of platelet-mediated force development plasma formation formation. AM J MED SCI 1991; May be assayed by thromboelastography.

The term “enhancing fibrin clot formation” refers to the rate or extent of fibrin clot formation measured for a test sample comprising a preparation of Factor VII or a Factor VII-related polypeptide and a preparation of a protein S inhibitor. Situations that are increased compared to the rate or extent of individual fibrin clot formation in a subject sample each containing only factor VII or a factor VII-related polypeptide or protein S inhibitor when tested in the same coagulation assay Is a term intended to include. Fibrin clot formation may be assayed as described above.

The term “reducing the clotting time” means the time of clot formation (clotting time) measured for a test sample comprising a preparation of factor VII or a factor VII-related polypeptide and a preparation of protein S inhibitor. A term intended to include an increased situation compared to an individual clotting time in a subject sample each containing only factor VII or a factor VII-related polypeptide or protein S inhibitor when tested in the same coagulation assay. It is. Clotting time may be assayed by means of standard Pt or aPTT assays known to those skilled in the art.

The term “reduced platelet count or activity” refers to the number of platelets (thrombocytes) present in a subject's plasma and the activity associated with biological clotting of such platelets. Say. The decrease in number may be due to, for example, increased platelet destruction, decreased platelet production, and more retention than the normal fraction of platelets in the spleen. Thrombocytopenia, for example, is defined as a platelet count that is less than 150,000 platelets / microliter; in general, the upper limit for normal platelet count is considered to be between 350,000 and 450,000 platelets / microliter. It is done. The platelet count may be counted by an automated platelet counter; this is a method well known to those skilled in the art. Syndromes due to a decrease in the number of platelets include, but are not limited to, thrombocytopenia and coagulopathy. “Activity” includes, but is not limited to, platelet aggregation, adhesion, and blood clotting activity. The decrease in activity includes, for example, glycoprotein abnormalities, abnormal membrane-cytoskeleton interactions, abnormal platelet granules, abnormal platelet blood clotting activity, abnormal signaling and secretion. Platelet activity, including aggregation, adhesion, and blood clotting activity, is measured by standard methods known to those skilled in the art, for example see Platelets. A Practical Approach, Ed. S. P. Watson & K. S. Authi: Clinical Aspects of Platelet Disorders (K. J. Clemetson) 15: 299-318, 1996, Oxford UniversityPress, William Edit, Sixth Edition. See Butler, Lichtman, Coller, Kipps & Seligsohn, 2001, McGraw-Hill. Syndromes due to reduced platelet activity include, but are not limited to, Granzman platelet asthenia, Bernard-Sulier syndrome, anticoagulant therapy, and thrombolytic treatment. “Lowered” refers to the number or activity of a test plasma sample as compared to the number or activity of a normal pooled plasma sample as measured in the same assay.

As used herein, the term “bleeding disorder” refers to any congenital, acquired, or induced defect of cellular or molecular origin that appears during the onset of bleeding. Represents. Examples of bleeding disorders include coagulation factor deficiency (eg, coagulation factor VIIl, IX, XI or VII deficiency), coagulation factor inhibitor, platelet function deficiency (eg, Grantsmann platelet asthenia, Bernard-Sulier syndrome), platelets Those caused by reduction, von Willebrand disease, and dilution of clotting proteins by bleeding and / or infusion, increased fibrinolysis, and decreased platelet count (eg, in multiple transfused subjects who have undergone surgery or trauma) A coagulation disorder such as, but not limited to.

Bleeding refers to the extravasation of blood from any part of the circulatory system.
The term “bleeding episodes” refers to a subject having unwanted, uncontrollable, and often excessive bleeding, and bleeding disorders associated with surgery, trauma, or other forms of tissue damage. Means including unwanted bleeding in the person. The onset of bleeding is basically in subjects with a normal coagulation system but suffering from (temporary) coagulation disorders, as well as in subjects with congenital or acquired coagulopathy or bleeding disorders Will occur. In hemostatic systems in hemophilia, bleeding in subjects with defective platelet function because essential coagulation “compounds” (eg, platelets or von Willebrand factor protein) are absent or abnormal. May be associated with bleeding caused by hemophilia. For example, subjects with extensive tissue damage associated with surgery or enormous trauma are uncontrollable by the immediate hemostatic demands of normal hemostasis mechanisms, and they are essentially ( Excessive bleeding will occur despite normal hemostasis mechanisms (before trauma or surgery). In addition, such frequently transfused subjects may experience (temporary) coagulopathy (ie, clotting protein dilution, fibrinolysis due to bleeding and / or infusion as a result of bleeding and / or infusion. And increase in platelet count). Bleeding may also occur in organs such as the brain, inner ear region, and eyes; in these, the potential for surgical hemostasis is limited and therefore a problem in achieving satisfactory hemostasis There is an area. Similar problems may arise in the process of performing biopsies from various organs (liver, lung, tumor tissue, gastrointestinal tract), as well as in laparoscopic surgery and radical retropubic prostatectomy. Common in all of these situations is that hemostasis is achieved by surgical techniques (sutures, clips, etc.) even when the bleeding is diffuse (eg hemorrhagic gastritis and massive uterine bleeding) Is difficult. Bleeding will also occur in anticoagulant subjects where hemostatic defects are induced by a given treatment; these bleedings are often acute and massive. Anticoagulant therapy is often performed to prevent thromboembolic diseases. Such treatments include heparin, other forms of proteoglycans, warfarin or other forms of vitamin K-antagonists, and other platelet aggregation inhibitors such as aspirin and eg antibodies or other GPllb / Illa activity inhibitors. I will. Also, bleeding is a so-called thrombolytic therapy that includes treatment in combination with antiplatelet agents (eg, acetylsalicylic acid), anticoagulants (eg, heparin), and fibrinolysin (eg, tissue plasminogen activator, protein S). It may be due to. In addition, bleeding episodes may include acute haemarthrose (joint bleeding), chronic haemophilia arthropathy, hematoma (eg, muscle, retroperitoneum, sublingual, and posterior pharynx), and other tissues Associated with surgery or trauma in subjects with bleeding, hematuria (bleeding from the renal tract), cerebral bleeding, surgery (eg, hepatectomy), tooth extraction, and gastrointestinal bleeding (eg, UGI bleeding), It is intended to include, but is not limited to, excessive bleeding that cannot be controlled. Onset of bleeding is an inhibitor of factor VIII; hemophilia A; hemophilia A and inhibitors; hemophilia B; factor VII deficiency; protein S inhibitor deficiency; thrombocytopenia; Deficiency (von Willebrand disease); severe tissue damage; severe trauma; surgery; laparoscopic surgery; hemorrhagic gastritis; biopsy collection; anticoagulant therapy; upper gastrointestinal bleedings (UGI); Or it may be related to stem cell transplantation. The onset of bleeding may occur in large amounts of uterine bleeding; in organs with a limited chance of mechanical hemostasis; in the brain; in the inner ear region; or in the eye. The terms “onset of bleeding” and “bleeding” are used interchangeably where appropriate.

In this context, the term “treatment” refers to preventing anticipated bleeding, such as in surgery, and inhibiting bleeding that has already occurred, such as in trauma, or It is intended to include both adjusting for purposes of minimization.
The “expected bleeding” described above may be bleeding that appears to occur in a particular tissue or organ, or it may be bleeding of unknown details. Thus, prophylactic administration of a preparation of factor VII or a factor VII-related polypeptide and a preparation of protein S inhibitor is included in the term “treatment”.

As used herein, the term “subject” is intended to mean any animal, particularly a mammal such as a human, and where appropriate, the term “patient”. And may be used interchangeably.
The invention also includes the use of Factor VII or FVII related polypeptides and protein S inhibitors within the scope of veterinary procedures.

The Factor VII or Factor VII-related polypeptide and protein S inhibitor as defined herein may be administered simultaneously or sequentially. The factor may comprise a preparation of factor VII or a factor VII-related polypeptide in a single dosage form containing both coagulation factors in a single dosage form or as a first unit dosage form in a second unit dosage form. As a kit of parts containing a protein S inhibitor preparation. The first or second or third other unit doses are referred to throughout this specification, but this is merely for convenience purposes, rather than indicating the preferred order of administration.

“Simultaneous” dosing of a preparation of factor VII or a factor VII-related polypeptide and a preparation of protein S inhibitor comprises administration of a coagulation factor in a single unit dosage form or administration of a first coagulation factor protein. Subsequent to this, administration of the second clotting factor protein means that the time has not been separated by more than 15 minutes, preferably 10 minutes, more preferably 5 minutes, more preferably more than 2 minutes. Either factor may be administered first.

“Sequential dosing” is the administration of the first clotting factor protein followed by administration of the second clotting factor protein for up to 2 hours, preferably 1-2 hours, more preferably up to 1 hour, more preferably 30. It means that the doses are administered in minutes apart from minutes to 1 hour, more preferably up to 30 minutes, more preferably from 15 to 30 minutes.
Either two unit dosage forms, or clotting factor protein, are administered first.
Preferably both products are injected through the same intravenous access.

One unit of factor VII is defined as the amount of factor VII present in 1 ml of normal plasma and corresponds to about 0.5 μg protein. Once activated, 50 units corresponds to about 1 g of protein.

“Deficiency” means that, for example, the presence or activity of, for example, factor VII in plasma is reduced compared to a normal healthy individual. The term may be used interchangeably with “reduced factor VII level” where appropriate.

“APTT” or “aPTT” means activated partial thromboplastin time (see, eg, Proctor RR, Rapport SI: The partial thromboplastin time with the fretting; a simple fretting test; J Clin Pathol 36: 212, 1961).

“Protein S inhibitor responsive syndrome” is any indication that is anticipated or present by the exogenous protein S inhibitor administered to a subject in need thereof, caused by the syndrome, It refers to a syndrome that will prevent, cure, or ameliorate symptoms or illness. Protein S inhibitor responsive syndrome may be treated with a composition according to the invention.

“Factor VII-responsive syndrome” is any indication that is caused, predicted, or present by the syndrome due to exogenous factor VII, preferably factor VIIa, administered to a subject in need thereof Means a syndrome that will prevent, cure, or ameliorate symptoms, or illness. Decreased clotting factor VIIl, IX, XI or VII levels, clotting factor inhibitors, defective platelet function (eg, Grantsmann platelet asthenia, Bernard-Sulier syndrome), thrombocytopenia, von Willebrand disease, and bleeding and / or Or syndromes caused by clotting disorders, such as those caused by dilution of clotting proteins by infusion, increased fibrinolysis, and decreased platelet count (eg, from a multiple transfused subject who has undergone surgery or trauma) However, it is not limited to these.

“Half-life” refers to the time required for the plasma concentration of factor VII or a factor VII-related polypeptide or protein S inhibitor to decrease from a certain value to half that value. .

“Primary hemostasis” is the initial generation of thrombin by FXa and TF: VIIa, followed by activation and activation of platelets to form an initial loose plug with adherent platelets by fibrin (final It means that it has not yet been stabilized (specifically by cross-linked fibrin). If not stabilized by fibrin formed during the second step of the hemostasis step, the plug is easily dissolved by the fibrinolytic system.

"Secondary hemostasis" or "maintained haemostasis" is a secondary, complete and major thrombin burst or generation that occurs at the activated platelet surface and that is factor VIIIa and VIIIa Means the subsequent formation of fibrin and stabilization of the initial platelet plug, catalyzed by factors. Stabilization of the plug with fibrin results in complete hemostasis.

“Complete hemostasis” means the formation of a stable and firm fibrin clot or plug at the site of injury that effectively stops bleeding and is not easily dissolved by the fibrinolytic system. In this context, the term hemostasis is used to describe complete hemostasis as described above.

The amount of total protein in the preparation may generally be measured by known methods, for example by measuring optical density. The amount of protein S inhibitor or factor VII protein (“antigen”) may be measured by generally known methods such as standard Elisa immunoassay methods. In general terms, such an assay involves contacting a solution of a standard containing, for example, a protein S inhibitor protein with an anti-thrombomodulin antibody immobilized on an elisa plate, followed by immobilized antibody- This is done by contacting the protein S inhibitor complex with an anti-protein S inhibitor secondary antibody having a marker, and measuring the amount thereof in the third step. The amount of each clotting factor may be measured using an appropriate antibody in a similar manner. The total amount of clotting factor protein present in the preparation is determined by adding the amount of individual clotting factor proteins.
In one embodiment, the preparation comprises an isolated clotting factor. In another embodiment, the preparation is essentially free of coagulation factor II and coagulation factor IIa (prothrombin and thrombin) and / or X or Xa factor.

As used herein, the term “isolated” refers to a clotting factor, such as a protein S inhibitor, that has been separated from the cells in which they were synthesized. Separation of the polypeptide from these source cells is accomplished by any method known in the art, removing the cell culture medium containing the desired product from the adherent cell culture; Including, but not limited to, removing adherent cells; Separation of the polypeptides from the medium in which they are naturally present may be achieved by any method known in the art, such as in the respective column of anti-factor VII or anti-protein S inhibitor antibody. Affinity chromatography; hydrophobic interaction chromatography; ion exchange chromatography; size exclusion chromatography; electrophoretic procedures (eg preparative isoelectric focusing (IEF)), solubility differences (eg ammonium sulfate precipitation), or extraction, etc. However, it is not limited to these.

Within the scope of the present invention, an “effective amount” of Factor VII or a Factor VII-related polypeptide and a protein S inhibitor together to cure, reduce, or partially reduce the disease and its complications. Defined as the amount of Factor VII or a Factor VII-related polypeptide (eg, FVIIa) and a protein S inhibitor sufficient to prevent or reduce bleeding or blood loss.

The term “factor VIIa activity” or “factor VIIa activity” includes the ability to generate thrombin; this term also includes the ability to generate thrombin on the surface of activated platelets in the absence of tissue factor. Including.

Abbreviations:
TF Tissue factor FVII Factor VII single chain, inactivated FVIIa Factor VII activated rFVIIa Recombinant factor VII activated TAFI TAFI enzyme precursor, inactivated PC protein S
APC Protein S activated PS Protein S
APS Protein S Activated TM Thrombomodulin PCI Protein S Natural Inhibitor

Compound preparation:
Human purified Factor Vila suitable for use in the present invention is described, for example, by Hagen et al., Proc. Natl. Acad. Sci. USA 83: 2412-2416, 1986, or as described in European Patent No. 200.421 (ZymoGenetics), preferably made by DNA recombination techniques.

Factor VII is described by Broze and Majerus (J. Biol. Chem. 255 (4): 1242-1247, 1980 and Hedner and Kisiel, J. Clin. Invest. 71: 1836-1841, 1983) and Hedner and Kisiel (J. Clin. Invest. 71: 1836-1841, 1983). These methods produce Factor VII without a detectable amount of other blood clotting factors. Still further purified factor VII preparation may be obtained by including additional gel filtration as a final purification step. Factor VII may then be converted to activated factor VIIa by known means (eg, several different plasma proteins such as protein S inhibitor Ia, IX, or Xa). Alternatively, passing Factor VII through ion-exchange chromatography such as Mono Q® (Pharmacia fine Chemicals) as described by Bjoern et al. (Research Disclosure, 269 September 1986, pp. 564-565). , May be activated.

Factor VII-related polypeptides may be produced by modification of wild-type factor VII or by recombinant techniques. A Factor VII-related polypeptide in which an amino acid has been altered when compared to wild-type factor VII is a nucleic acid sequence that encodes wild-type factor VII, changes an amino acid codon in a nucleic acid that encodes native factor VII, or Any of the removal of several amino acid codons may be produced by modification by well-known means (eg site-directed mutagenesis).

It will be apparent to those skilled in the art that substitutions can be made outside of the region important for the function of the factor VIIa or protein S inhibitor molecule-still produce active polypeptides. Amino acid residues that are essential for the activity of factor VII or a factor VII-related polypeptide, or protein S inhibitor and thus preferably do not undergo substitution are site-directed mutagenesis or alanine scanning mutagenesis (eg, Cunningham And Wells, 1989, Science 244: 1081-1085) and can be identified according to procedures known in the art. In the latter technique, mutations are introduced into all positively charged residues in the molecule, and the resulting mutant molecule is cross-linked with a coagulant to identify amino acid residues that are important for the activity of the molecule. Each is tested for activity. Also, substrate-enzyme interaction sites can be detected by nuclear magnetic resonance analysis, crystallography, or photoaffinity labeling (eg, de Vos et al., 1992, Science 255: 306-312; Smith et a /., 1992, Journal of Molecular Biology 224: 899-904; Wlodaver et al., 1992, FEBS Letters 309: 59-64), and the like.

Introduction of mutations into a nucleic acid sequence to replace one nucleotide with another may be accomplished by site-directed mutagenesis using any method known in the art. Particularly useful are procedures that utilize a supercoiled double stranded DNA vector with an insert of interest and two synthetic primers containing the desired mutation. Oligonucleotide primers, each complementary to the opposite strand of the vector, were extended during temperature cycling by Pfu DNA polymerase. Upon primer incorporation, mutant plasmids are produced that contain staggered nicks. After temperature cycling, the product is treated with Dpnl that is specific for methylated and hemimethylated DNA to digest the parental DNA template and select for synthetic DNA containing the mutation. Other procedures known in the art for creating, identifying, and isolating variants may be used, such as gene mixing techniques or phage display techniques.

Separation of the polypeptide from these source cells is accomplished by any method known in the art, removing the cell culture medium containing the desired product from the adherent cell culture; Including, but not limited to, removing adherent cells;

Optionally, the factor VII or factor VII-related polypeptide may be further purified. Purification involves affinity chromatography such as, for example, anti-factor VII antibody columns (see, eg, Wakabayashi et al., J. Biol. Chem. 261: 11097, 1986; and Thim et al., Biochem. 27: 7785, 1988); hydrophobic interactions Chromatography; ion exchange chromatography; size exclusion chromatography; electrophoretic procedures (eg, including but not limited to preparative isoelectric focusing (IEF), solubility differences (eg ammonium sulfate precipitation) or extraction, etc. It may be achieved using any method known in the art, generally, Scopes, Protein Purification, Springer-Verlag, New York, 198 And Protein Purification, JC Janson and Lars Ryden, editors, VCH Publishers, New York, 1989. Following purification, the preparation is non-factor VII or factor VII related to host cells. The polypeptide comprises less than about 10% by weight, more preferably less than about 5%, and most preferably less than about 1%.

Factor VII or a factor VII-related polypeptide is activated by proteolytic cleavage using factor XIa or other proteases with trypsin-like specificity such as factor IXa, kallikrein, factor Xa, and thrombin Also good. For example, Osterud et al. , Biochem. 11: 2853 (1972); Thomas, U .; S. Patent No. 4,456, 591; and Hedner et al. , J. et al. Clin. Invest. 71: 1836 (1983). Alternatively, Factor VII or Factor VII-related polypeptide can be activated by passing it through ion exchange chromatography, such as Mono Q® (Pharmacia). The resulting activated factor VII or factor VII-related polypeptide may then be formulated and administered as described below.

Protein S is described in, for example, Haley et al. , J. et al. Biol. Chem. , 264; 16303, 1989, and Turkay et al. , Thromb. Haemost. 81; 727 1999 can be isolated or produced.

Protein S inhibitors in the form of polypeptides are preferably produced by recombinant production methods in order to avoid the use of products derived from blood or tissue at risk of disease transmission. Methods for preparing recombinant proteins (including conventional molecular biology, microbiology, and recombinant DNA techniques) are within the skill of the artisan.
Such techniques are explained fully in the literature. For example, Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York DNA Cloning (herein "Sambrook et al, 1989."): A Practical Approach, Volumes I and 11 / D. N. Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgs eds. (1985)); Higgins, eds. (1984)); Animal Cell Culture (R. I. Freshney, ed. (1986)); Immobilized Cells And Enzymes (IRL Press, (1986)). See Perbal, A Practical Guide To Molecular Cloning (1984).

Methods for producing antibodies are generally known in the art, for example, the literature (Harboe and Ingild, In NH Axelsen, J. Krll, and B. Weeks, editors, A Manual of Quantitative I Quantitative). See Scientific Publications, 1973, Chapter 23, or Johnstone and Thorpe, Immunochemistry in Practice, Blackwell Scientific Publications, 1982 (page 31). Preferably, the antibody is a monoclonal antibody. Monoclonal antibodies are described in, for example, E.I. Harlow and D.H. It can be prepared according to the method of Lane, editors, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, New York.

As will be appreciated by those skilled in the art, it is preferred to use protein S inhibitors and factor VII polypeptides that are isogenic to the subject in order to reduce the risk of inducing an immune response. The invention also includes the use of such protein S inhibitors and factor VII polypeptides within the veterinary procedures.

Pharmaceutical Compositions and Methods of Use The preparations of the present invention may, for example, reduce coagulation factor VIII, IX, XI or VII levels, coagulation factor inhibitors, platelet function defects (eg, Grantsman platelet asthenia and Bernard-Sulier syndrome). ), Thrombocytopenia, von Willebrand disease, and dilution of clotting proteins by bleeding and / or infusion, increased fibrinolysis, and decreased platelet count (eg, from multiple transfused subjects who have undergone surgery or trauma) ) May be used to treat any factor VII-responsive syndrome, including but not limited to syndromes caused by coagulation disorders such as those caused by coagulation disorders.
A pharmaceutical composition comprising a preparation of factor VII or a factor VII-related polypeptide according to the invention and a preparation of a protein S inhibitor is administered parenterally mainly for prophylactic and / or therapeutic treatments. Is contemplated.
Preferably, the pharmaceutical composition is administered parenterally, ie intravenously, subcutaneously or intramuscularly; intravenous is most preferred. They may also be administered by continuous or pulsatile infusion.

A pharmaceutical composition or formulation according to the invention is formulated either in a single unit dosage form or in a kit part, preferably in a pharmaceutically acceptable carrier, preferably an aqueous carrier or diluted. A Factor VII or Factor VII-related polypeptide and a protein S inhibitor dissolved in a fluid. Briefly, a pharmaceutical composition suitable for use in accordance with the present invention is a factor VII or factor VII-related polypeptide, or a protein S inhibitor, or a factor VII or factor VII-related polypeptide in combination with a protein S inhibitor Is made, preferably in purified form, mixed with a suitable adjuvant and a suitable carrier or diluent. Various water-soluble carriers such as water, buffered water, 0.4% physiological saline, 0.3% glycine may be used. The preparations of the present invention can also be formulated using a non-aqueous carrier, such as in the form of a gel or as a liposome preparation, for delivery or targeting to the site of injury. Liposome preparations are generally described, for example, in US Pat. Nos. 4,837,028, 4,501,501,728, and 4,975,282. The composition may be sterilized by conventional, well-known sterilization techniques. The resulting aqueous solution may be packed for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being mixed with a sterile aqueous solution prior to administration.

The composition comprises a pH adjusted and buffered drug and / or a tonicity adjusted drug, such as sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc. It may contain (but is not limited to) pharmaceutically acceptable auxiliary substances or adjuvants.

The formulation may further include one or more diluents, emulsifiers, preservatives, buffers, excipients, etc., provided in the form of a liquid, powder, emulsion, controlled release, etc. May be. One of ordinary skill in the art can use the compositions of the present invention in a suitable manner and in Remington's Pharmaceutical Sciences, Gennaro, ed. , Mack Publishing Co. , Easton, PA, may be prescribed according to approved practices such as those disclosed in 1990
In this way, a typical pharmaceutical composition for intravenous infusion could be made to contain 250 ml of sterile Ringer's solution and 10 mg of the preparation.

A composition comprising a preparation of the invention can be administered for prophylactic and / or therapeutic treatments. In therapeutic applications, the composition is in an amount sufficient to cure, reduce or partially reduce the clinical symptoms of the disease and its complications for a subject already suffering from the disease. Administered as described above. An amount sufficient to accomplish this is defined as a “therapeutically effective amount”. Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be appreciated that the determination of an appropriate dose can be achieved using routine tests by building a matrix from the values and testing different points of the matrix.

Local delivery, eg topical application, of the preparation of the present invention includes, for example, spraying, perfusion, dual balloon catheters, stents, vascular grafts or stents, hydrogels used to coat balloon catheters, or others Well, it may be done by established methods. In any event, the pharmaceutical composition should provide a quantity of preparation sufficient to effectively treat the condition.

The concentration of factor VII or factor VII-related polypeptide, protein S inhibitor, or factor VII or factor VII-related polypeptide in combination with protein S inhibitor in these formulations is broad, ie about 0.5% by weight Can vary from less than, usually at least about 1% by weight or more to as much as 15 or 20% by weight, depending mainly on the liquid volume, viscosity, etc., according to the particular method of administration selected.
Administration by injection or infusion, especially injection, is preferred. Thus, factor VII or factor VII-related polypeptide and protein S inhibitor is one of the dissolved lyophilized powder or liquid formulation comprising both factor VII or factor VII-related polypeptide and protein S inhibitor. Of one lysed form, or one lysed lyophilized powder or liquid formulation comprising Factor VII or a Factor VII-related polypeptide and a lysed lyophilized powder or liquid formulation comprising a protein S inhibitor It is prepared in a form suitable for intravenous administration, such as one of the other dosage forms.

It is understood that the amount of Factor VII or Factor VII-related polypeptide, and the amount of protein S inhibitor, both comprise an effective amount of aggregate to treat the onset of bleeding.

It must be taken into account that the materials of the present invention are generally used in serious illness or injury situations, i.e. in life-threatening or potentially life-threatening situations. In such cases, these compositions are administered in substantial excess by the treating physician in view of the minimization of foreign substances and the general lack of immunogenicity of factor VIIa and protein S inhibitors in humans. It may be possible and desirable.

In a prophylactic application, a composition comprising a preparation of Factor VII or a Factor VII-related polypeptide and a preparation of a protein S inhibitor is provided to a subject who is susceptible to or otherwise at risk for a disease state or injury. Administered to enhance the subject's own clotting ability. Such an amount is defined to be a “prophylactically effective dose”. It will be appreciated that the amount of Factor VII or Factor VII-related polypeptide, and the amount of protein S inhibitor, together comprise an amount of aggregate effective to prevent the onset of bleeding.

Single or multiple administrations of the compositions are carried out with dose levels and pattern being selected by the therapist. The composition may be administered one or more times per day or week. An effective amount of such a pharmaceutical composition is an amount that provides a clinically significant effect on the development of bleeding.
Such amount will depend, in part, on the particular condition being treated, the age, weight, and general health of the subject, as well as other factors apparent to those of skill in the art.

The compositions of the invention are generally administered in a single dose before the expected bleeding or at the start of the bleeding. Preferably, however, it may be given repeatedly (in multiple doses) at intervals of 2-4-6-12 hours, depending on the dose given and the subject's symptoms.

For therapies associated with careful treatment, factor VII or a factor VII-related polypeptide, and protein S inhibitor are typically added within about 24 hours prior to intervention and 7 Administer for more than a day. Administration as a coagulant may be by a variety of routes as described herein.

The composition is in the form of a single preparation (single dosage form) containing both an appropriate concentration of a Factor VII or Factor VII-related polypeptide preparation and a protein S inhibitor preparation. Also good. The composition may also be in the form of a kit of parts comprising a first unit dosage form comprising a preparation of Factor VII or a Factor VII-related polypeptide and a second unit dosage form comprising a preparation of a protein S inhibitor. There may be. In this case, the factor VII or factor VII-related polypeptide and the protein S inhibitor are preferably one after the other, preferably within about 15 minutes of each other, such as within 10 minutes of each other, or preferably within 5 minutes, or more Preferably they should be administered within 2 minutes of each other.
Either of the two unit dosage forms can be administered first.

The kit includes at least two separate pharmaceutical compositions. The kit includes container means for containing separate compositions, such as separate bottles or separate foil packets. Typically, the kit includes instructions for administration of the separate components. The kit when separate components are administered, preferably in different dosage forms, at different dosage intervals, or when titration of a combination of individual components is required by the prescribing physician The form is particularly advantageous.

The amount of Factor VII or Factor VII-related polypeptide and protein S inhibitor administered in accordance with the present invention may vary in ratio between about 1: 100 to about 100: 1 (w / w). Thus, the ratio of factor VII to protein S inhibitor is, for example, about 1: 100, or 1:90, or 1:80, or 1:70, or 1:60, or 1:50, or 1:40, or 1:30, or 1:20, or 1:10, or 1: 5, or 1: 2, or 1: 1, or 2: 1, or 5: 1, or 10: 1, or 20: 1, or 30: 1, or 40: 1, or 50: 1, or 60: 1, or 70: 1, or 80: 1, or 90: 1, or 100: 1; or about 1:90 to about 1: 1. Or about 1:80 to about 1: 2, or about 1:70 to about 1: 5, or about 1:60 to about 1:10, or about 1: Between about 50 and about 1:25, or between about 1:40 and about 1:30. Is between about 90: 1 and about 1: 1, or between about 80: 1 and about 2: 1, or between about 70: 1 and about 5: 1, or between about 60: 1 and about 10 :. 1 or between about 50: 1 and about 25: 1, or between about 40: 1 and about 30: 1.

The dose of Factor VII or Factor VII-related polypeptide is about 0.05 mg to 70 kg subject as a loading dose and maintenance dose, depending on the subject's weight, symptoms, and severity of symptoms. It varies in a range corresponding to about 500 mg / day of wild-type thrombomodulin, such as from about 1 mg to about 200 mg / day, or such as from about 5 mg to about 175 mg / day.

The dose of protein S inhibitor is about 0.05 mg to about 500 mg / day for a 70 kg subject as a loading dose and maintenance dose, depending on the subject's weight, symptoms, and severity of symptoms. Of wild-type protein S inhibitors, eg, ranging from about 1 mg to about 200 mg / day, or such as from about 1 mg to about 175 mg / day.

The combination of factor VII or a factor VII-related polypeptide and a protein S inhibitor shows a synergistic effect in an in vitro clot firmness assay and a fibrinolysis time assay.
In addition, the combination of factor VII or a factor VII-related polypeptide and a protein S inhibitor results in the formation of a stable fibrin clot, increased half clot lysis time, increased clot strength, and increased resistance to fibrinolysis. Shows a synergistic effect.

The composition may be in the form of a single preparation comprising both an appropriate concentration of factor VII or a factor VII-related polypeptide and a protein S inhibitor. The composition may also be in the form of a kit comprising a first unit dosage form comprising Factor VII or a Factor VII-related polypeptide and a second unit dosage form comprising a protein S inhibitor. In this case, the Factor VII or Factor VII-related polypeptide and the protein S inhibitor are preferably within about 1-2 hours of each other, for example within 30 minutes of each other, or preferably within 10 minutes, or more preferably 5 minutes of each other. Should be administered sequentially. Either of the two unit dosage forms can be administered first.

Since the present invention relates to preventing or treating the onset of bleeding or coagulation treatment by treating in combination with active ingredients that may be administered separately, the present invention relates to separate pharmaceutical compositions in kit form. Also related to combining. The kit includes at least two separate pharmaceutical compositions. The kit includes container means for containing separate compositions, such as separate bottles or separate foil packets. Typically, the kit includes instructions for administration of the separate components. The kit when separate components are administered, preferably in different dosage forms, at different dosage intervals, or when titration of a combination of individual components is required by the prescribing physician The form is particularly advantageous.

Assay method:
Test for factor VIIa activity:
An assay suitable for selecting the appropriate Factor VIIa variant by testing for Factor VIIa activity can be performed as a simple preliminary in vitro test:

In Vitro Hydrolysis Assay Specific activity may be assayed with native (wild type) Factor VIIa and variant Factor VIIa (both hereinafter referred to as “Factor VIIa”). They may also be assayed in parallel to compare their specific activities directly. The assay is performed in microtiter plates (MaxiSorp, Nunc, Denmark). Final concentration of 1 mM chromogenic substrate D-Ile-Pro-Arg-p-nitroanilide (S-2288, Chromogenix, Sweden), Factor VIIa (final concentration 100 nM) 0.1 M NaCI, 5 mM CaCl ₂ , and 1 mg Add to a solution of 50 mM Hepes, pH 7.4 containing / ml bovine serum albumin. Absorbance at 405 nm is measured continuously in a SpectraMax ™ 340 plate reader (Molecular Devices, USA). The absorbance generated during the 20 minute incubation is used to calculate the ratio between the mutant and wild type factor VIIa activity after subtracting the absorbance of empty wells without enzyme:

Ratio = (A ₄₀₅ nm Factor VIIa variant) / (A ₄₀₅ nm Factor VIIa wild type).

Based on the results, a Factor VIIa variant that has activity comparable to or higher than that of native Factor VIIa, for example, has a ratio between the activity of the variant and the activity of native Factor VII (wild type FVII). , A variant that is around a numerical value exceeding 1.0 (around, versus above 1.0).

The activity of factor VIIa or factor VIIa variant may also be measured using a physiological substrate such as factor X, suitably at a concentration of 100-1000 nM, in which case production of factor Xa is Measured after adding a suitable chromogenic substrate (eg, S-2765). In addition, activity assays may be performed at physiological temperatures.

In Vitro Proteolytic Assays Natural (wild type) Factor VIIa and Factor VIIa variants (both hereinafter referred to as “Factor VIIa”) are assayed in parallel to directly compare their specific activities. . The assay is performed in microtiter plates (MaxiSorp, Nunc, Denmark). Incubate for 15 minutes with 100 μl of 50 mM Hepes, pH 7.4 containing 0.1 M NaCl, 5 mM CaCl 2 and 1 mg / ml bovine serum albumin of Factor VIIa (10 nM) and Factor X (0.8 μM). Cleavage of factor X is then stopped by adding 50 μl of 50 mM Hepes, pH 7.4 containing 0.1 M NaCl, 20 mM EDTA, and 1 mg / ml bovine serum albumin. The amount of factor Xa produced is determined by the addition of the chromogenic substrate ZD-Arg-Gly-Arg-p-nitroanilide (S-2765, Chromogenix, Sweden) (final concentration 0.5 mM). Absorbance at 405 nm is measured continuously in a SpectraMax ™ 340 plate reader (Molecular Devices, USA). The absorbance generated during 10 minutes is used to calculate the ratio between the proteolytic activity of the mutant and wild type factor VIIa after subtracting the absorbance of empty wells without FVIIa:

Ratio = (A ₄₀₅ nm Factor VIIa variant) / (A ₄₀₅ nm Factor VIIa wild type).

Based on the results, a Factor VIIa variant that has activity comparable to or higher than that of native Factor VIIa, for example, has a ratio between the activity of the variant and the activity of native Factor VII (wild type FVII). May be identified as a variant around a numerical value exceeding 1.0.

Thrombin generation assay:
The ability of factor VII or factor VII-related polypeptides, or protein S inhibitors or protein S inhibitor-related polypeptides (eg, variants) to generate thrombin, is related to all relevant coagulation factors and physiological concentrations of inhibitors and Which can be measured in assays involving activated platelets (as described on page 543 of Monroe et al. (1997) Brit. J. Haematol. 99, 542-547, which is described herein) Incorporated by reference).

Test for protein S activity:
An assay suitable for providing a means for selecting a suitable protein S inhibitor for use in the present invention by testing protein S activity is described, for example, by Walker et al. , J. et al. Biol. Chem. 261: 10941, 1986 (“Protein S Assay”).

The invention is further illustrated by the following examples, which are not to be construed as limiting the scope of protection. In the foregoing description, and in the following examples, the disclosed features are both material and material, both material and material, for realizing the various forms of the invention. is there.

Example 1
Combining VIIa clotting factor and anti-protein S antibody improves the stability of hemostatic clots.

Method:
Clot lysis assay: Innovin (Dade Behring, 2000 fold dilution), rFVIIa (Novo Norddisk A / S Bagsvaard, Denmark, various concentrations), and t-PA (American Diagnostica, buffer 8M) Normal human plasma diluted 10-fold with 20 mM HEPES, 150 mM NaCl, 5 mM CaCl, pH 7.4) is added to a 96-well ELISA plate and the turbidity at 650 nm is measured over time at room temperature. Where indicated, monoclonal anti-protein S antibodies were included.

result:
Clot lysis assay: Addition of FVIIa results in a dose-dependent extension of clot lysis time. Determine the optimal concentration (nM) of FVIIa. In the presence of FVIIa at the optimal concentration, the addition of anti-protein S antibody results in further prolongation of clot lysis time.

These results demonstrate that adding FVIIa and protein S inhibitor to plasma in a synergistic fashion improves clot fibrinolysis resistance.

Claims (51)

A pharmaceutical composition comprising Factor VII or a Factor VII-related polypeptide and a protein S inhibitor. 2. The composition of claim 1, wherein the factor VII or factor VII-related polypeptide is a factor VII-related polypeptide. 4. The composition of claim 2, wherein the factor VII-related polypeptide is a factor VII amino acid sequence variant. 4. The composition of claim 2 or claim 3, wherein the ratio between the activity of the factor VII-related polypeptide and the activity of native human factor VIIa (wild type FVIIa) is described herein. A composition that is at least about 1.25 when tested in the “in vitro hydrolysis assay” as described. 2. The composition of claim 1, wherein the factor VII or factor VII-related polypeptide is factor VII. 6. The composition of claim 5, wherein the factor VII is human factor VII. The composition of claim 6, wherein the factor VII is recombinant human factor VII. The composition according to any one of claims 1 to 7, wherein the factor VII or factor VII-related polypeptide is an active form thereof. 9. The composition of claim 8, wherein the factor VII is recombinant human factor VIIa. 10. The composition according to any one of claims 1 to 9, wherein the protein S inhibitor is a small organic molecule having a molecular weight of less than 5000 kDa. The composition according to any one of claims 1 to 9, wherein the protein S inhibitor is a polypeptide, an oligopeptide, a peptide or a fragment thereof. 10. The composition according to any one of claims 1 to 9, wherein the protein S inhibitor is an antibody or a Fab, Fab ', F (ab') 2, or F (v) fragment of an antibody. A composition. The composition of claim 12, wherein the antibody is a monoclonal antibody. 14. The composition of claim 13, wherein the monoclonal antibody is a humanized antibody. 14. The composition of claim 13, wherein the monoclonal antibody is a fully human antibody. 16. The composition of any one of claims 1-15, wherein the factor VII or factor VII-related polypeptide and the protein S inhibitor are about 100: 1 and about 1: 100 (w / w VII: Protein S inhibitor). 17. A composition according to any one of the preceding claims, further comprising a pharmaceutically acceptable excipient suitable for injection or infusion, in particular for injection. A kit of parts containing a therapeutic agent for the onset of bleeding,
a) an effective amount of a preparation of Factor VII or Factor VII-related polypeptide in a first unit dosage form, and a pharmaceutically acceptable carrier;
b) an effective amount of a protein S inhibitor preparation in a second unit dosage form, and a pharmaceutically acceptable carrier; and c) a container means for containing said first and second dosage forms; A composition comprising 19. A kit according to claim 18, wherein the factor VII or factor VII-related polypeptide is a factor VII-related polypeptide. 21. The kit of claim 19, wherein the Factor VII related polypeptide is a Factor VII amino acid sequence variant. 21. A kit according to claim 19 or claim 20, wherein the ratio between the activity of the factor VII-related polypeptide and the activity of native human factor VIIa (wild type FVIIa) is described herein. A kit that is at least about 1.25 when tested in a “in vitro hydrolysis assay” as described. 19. The kit according to claim 18, wherein the factor VII or factor VII-related polypeptide is factor VII. 24. The kit of claim 22, wherein the factor VII is human factor VII. 24. The kit of claim 23, wherein the factor VII polypeptide is a recombinant human factor VII. The kit according to any one of claims 18 to 24, wherein the factor VII or factor VII-related polypeptide is an active form thereof. 26. The kit of claim 25, wherein the factor VII is recombinant human factor VIIa. 27. Kit according to any one of claims 18 to 26, wherein the protein S inhibitor is a small organic molecule having a molecular weight of less than 5000 kDa. 27. The kit according to any one of claims 18 to 26, wherein the protein S inhibitor is a polypeptide, an oligopeptide, a peptide or a fragment thereof. 27. The kit according to any one of claims 18 to 26, wherein the protein S inhibitor is an antibody or a Fab, Fab ′, F (ab ′) 2, or F (v) fragment of an antibody. kit. 30. The kit of claim 29, wherein the antibody is a monoclonal antibody. 31. The kit according to claim 30, wherein the monoclonal antibody is a humanized antibody. 31. The kit according to claim 30, wherein the monoclonal antibody is a fully human antibody. 33. The kit of any one of claims 18-32, wherein the factor VII or factor VII-related polypeptide and protein S inhibitor are about 100: 1 and about 1: 100 (w / w VII: A kit present in a mass ratio between (protein S inhibitor). Use of factor VII or a factor VII-related polypeptide in combination with a protein S inhibitor for the manufacture of a medicament for treating the development of bleeding. Use of a composition according to any one of claims 1 to 17 for the manufacture of a medicament for treating the onset of bleeding. 36. Use according to claim 34 or claim 35, wherein the drug is for reducing clotting time. 36. Use according to claim 34 or claim 35, wherein the drug is for extending clot lysis time. 36. Use according to claim 34 or claim 35, wherein the drug is for increasing clot strength. Use according to any of claims 34 to 38, wherein the drug is formulated for injection or infusion, in particular for injection. 40. Use according to any one of claims 34 to 39, wherein the onset of bleeding is due to trauma or surgery or a decrease in platelet count or activity. 41. Use according to any one of claims 34 to 40, wherein the drug is in a single dosage form. 35. The drug is prepared in the form of a first unit dosage form comprising a preparation of factor VII or a factor VII-related polypeptide and a second unit dosage form comprising a preparation of a protein S inhibitor. 41. Use according to any one of 40. A method for treating the onset of bleeding in a subject, said method comprising, for a subject in need thereof, a first amount of a Factor VII or Factor VII-related polypeptide preparation; Administering a second amount of a preparation of protein S inhibitor, wherein the first and second amounts are both effective for treating bleeding. A method for reducing the clotting time in a subject, said method comprising, for a subject in need thereof, a first amount of a preparation of factor VII or a factor VII-related polypeptide, a protein, Administering a second amount of a preparation of S inhibitor, wherein the first and second amounts are both effective to reduce clotting time. A method for enhancing hemostasis in a subject, said method comprising, for a subject in need thereof, a first amount of a preparation of factor VII or a factor VII-related polypeptide, protein S Administering a second amount of a preparation of inhibitor, wherein said first and second amounts are both effective to enhance hemostasis. A method for prolonging the clot lysis time in a subject, said method comprising, for a subject in need thereof, a first amount of a preparation of factor VII or a factor VII-related polypeptide, A second amount of a protein S inhibitor preparation, wherein the first and second amounts are both effective to prolong clot lysis time. A method for increasing clot strength in a subject, said method comprising, for a subject in need thereof, a first amount of a preparation of factor VII or a factor VII-related polypeptide; Administering a second amount of a preparation of protein S inhibitor, wherein the first and second amounts are both effective to increase clot strength. 48. The method of any one of claims 43 to 47, wherein the factor VII or factor VII-related polypeptide and the protein S inhibitor are administered in a single dosage form. 48. The method according to any one of claims 43 to 47, wherein the factor VII or factor VII-related polypeptide and the protein S inhibitor comprise a preparation of factor VII or factor VII-related polypeptide. And a second unit dosage form comprising a preparation of a protein S inhibitor. 50. The method of claim 49, wherein the first unit dosage form and the second unit dosage form are administered at a time not exceeding 15 minutes. A kit comprising a therapeutic agent for the onset of bleeding,
a) an effective amount of Factor VII or a Factor VII-related polypeptide, and an effective amount of a protein S inhibitor, and a single unit dosage form of a pharmaceutically acceptable carrier; and
b) a kit comprising container means for containing said single unit dosage form.